Vivanza Biosciences Quarterly Results for Trading Insights
In Mar 2026, Vivanza Biosciences (VIVANZA) reported revenue ₹6 Cr and net profit ₹0 Cr — revenue +500.0% YoY. For annual financials, live price and key ratios, visit VIVANZA share price screener.
VIVANZA Quarterly Results — Revenue, Profit & EPS Highlights
Vivanza Biosciences latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore Vivanza Biosciences stock price data download to track price trends across different timeframes.
- Revenue of ₹6 Cr in Mar 2026 (-89.1% vs Sept 2025, +500.0% vs Mar 2025)
- Operating Margin of -4.0% in Mar 2026 (-5.0pp vs Sept 2025)
- Earnings Per Share of ₹-0.11 in Mar 2026 (-178.6% vs Sept 2025)
Vivanza Biosciences Quarterly Results — Revenue, EBITDA, Net Profit & EPS
VIVANZA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 6 | 55 | 1 | 9 | 45 | -89.1% | 500.0% |
| Net Profit (₹ Cr) | 0 | 1 | -1 | 0 | 0 | - | - |
| EBITDA (₹ Cr) | 0 | 1 | -1 | 0 | 0 | - | - |
| EPS (₹) | -0.11 | 0.14 | -0.25 | 0.02 | 0.05 | - | - |
| Operating Margin (%) | -4.0% | 1.0% | -200.0% | 2.0% | 0.0% | - | - |
VIVANZA Share Price Trend — 1-Year Movement Across Quarterly Results
Vivanza Biosciences 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Compare with VIVANZA fair price to assess whether the stock is under or overvalued.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
VIVANZA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Vivanza Biosciences latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹442,581.33 Cr | 1788.5 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 158.3 |
|
Divis Laboratories
Mar 2026 |
₹179,363.85 Cr | 6576.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 232.3 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹153,579.77 Cr | 4368.5 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 379.5 |
|
Cipla
Mar 2026 |
₹114,559.46 Cr | 1375.2 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 200.2 |
|
Dr Reddys Laborator…
Mar 2026 |
₹110,089.41 Cr | 1263.3 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 476.7 |
All amounts in ₹ Crores